Mineralys Therapeutics (NASDAQ:MLYS) is gearing up to announce its quarterly earnings on Tuesday, 2025-08-12. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Mineralys Therapeutics will report an earnings per share (EPS) of $-0.76.
The market awaits Mineralys Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Past Earnings Performance
The company's EPS beat by $0.19 in the last quarter, leading to a 1.2% increase in the share price on the following day.
Here's a look at Mineralys Therapeutics's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.98 | -1.08 | -0.83 | -0.70 |
| EPS Actual | -0.79 | -0.98 | -1.13 | -0.83 |
| Price Change % | 1.0% | -4.0% | -10.0% | -23.0% |
Tracking Mineralys Therapeutics's Stock Performance
Shares of Mineralys Therapeutics were trading at $13.0 as of August 08. Over the last 52-week period, shares are up 12.51%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
To track all earnings releases for Mineralys Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
